Arthralgia and a Positive ANA on Hydralazine: Stop the Drug That's Keeping Him Out of the Hospital
The medication causing his new joint pain and pleurisy is also one of the only things keeping his heart failure out of the hospital. Stopping it is the textbook answer; his renal function is why the textbook answer isn't actually available to him.
W.T., a 61-year-old man, retired from a postal carrier route, with HFrEF (EF 28%) and stage 3b chronic kidney disease that has made him intolerant of ACE inhibitors, ARBs, and sacubitril/valsartan on three separate documented attempts, has been on hydralazine/isosorbide dinitrate for the past eleven months as his renin-angiotensin-system-directed heart failure therapy, added specifically because his creatinine rose unacceptably each time an ACE inhibitor or ARNI was tried. Over the past six weeks he has developed new bilateral small-joint arthralgia, pleuritic chest pain, and a low-grade fever, with a newly positive ANA and a strongly positive anti-histone antibody, but a negative anti-dsDNA and normal complement — a serologic pattern that is close to diagnostic for drug-induced lupus rather than idiopathic SLE. He mentioned the joint pain almost in passing, framing it as “probably just getting older”; his daughter, a nurse who comes to his appointments, pushed for the ANA panel, which is why this is being addressed at six weeks rather than several months further in. No ANCA has been sent and no urine sediment has been examined this visit.
His echocardiogram six weeks ago, before symptoms began, showed a stable EF and no decompensation, and he has had zero heart failure hospitalizations in the eleven months since hydralazine/ISDN was started — a real, measurable clinical benefit in a patient who has already failed every guideline-preferred alternative for reasons that haven't changed. Hydralazine-induced lupus is well described, dose- and duration-dependent, and concentrated in slow acetylators, with an incidence in the range of five to eight percent on sustained therapy; its serologic signature — anti-histone positive, anti-dsDNA negative — is exactly what his labs show, and it generally resolves over weeks to months once the drug is withdrawn. The reassurance usually attached to that picture, that drug-induced lupus spares the kidneys, is a statement about the class and not about this drug. Hydralazine separately causes an ANCA-associated vasculitis with pauci-immune crescentic glomerulonephritis; Aeddula and colleagues' two-patient report is representative of a literature in which anti-MPO or anti-PR3 positivity accompanies dialysis-requiring acute kidney injury on a background of pre-existing chronic disease, and in which a positive anti-MPO has been proposed as the marker predicting the pulmonary-renal end of the spectrum. Nothing in his workup so far distinguishes the syndrome that spares kidneys from the one that destroys them, and he is the patient with the least renal reserve to spend finding out.
Joint consult, the drug that works and the drug that’s hurting him
His serology is about as close to textbook drug-induced lupus as this gets — positive ANA, strongly positive anti-histone, negative anti-dsDNA, normal complement, six weeks after starting a drug that induces this in something like five to eight percent of people who stay on it, concentrated in slow acetylators. The standard answer is to stop the causative drug. I think we owe him that answer plainly, even knowing what it costs him.
I'm not disputing the diagnosis — the serology is what it is. What I want named plainly is what stopping this drug actually means for him: he's failed ACE inhibitors, ARBs, and sacubitril/valsartan, all three, on real renal grounds that haven't changed. Eleven months on hydralazine and ISDN, zero heart failure hospitalizations. That's not a number to set aside lightly.
Classical drug-induced lupus stays musculoskeletal and serosal, and his presentation is exactly that. Given what he'd lose, I'd try continuing at a reduced dose with symptom control before pulling his only working heart failure option.
I don't think this can be decided today at all, and I want to be specific about why rather than just counselling delay. The sentence the continuation argument is resting on — drug-induced lupus spares the kidneys — is true of the class and not of this drug. Hydralazine causes a second, separate syndrome: ANCA-associated vasculitis with pauci-immune crescentic glomerulonephritis, anti-MPO or anti-PR3 positive. Aeddula reported two patients on hydralazine with crescentic disease on biopsy, both needing dialysis, one from a baseline creatinine not much worse than his.
His joints and his anti-histone titer will not tell us which syndrome he has. ANCA serology and a urine sediment will, and neither has been sent. Send both today. If they're clean, a monitored reduced-dose continuation is a defensible real-world compromise and I'd support it — but followed on ANCA and urine, not on anti-histone, which tracks the syndrome that isn't the dangerous one. If he's ANCA-positive or has an active sediment, this stops regardless of what it costs his heart failure, because at stage 3b he does not have a kidney to spare.
Agreed: send ANCA serology and a urine sediment today, continue hydralazine/isosorbide dinitrate at a reduced dose in the interval rather than stopping a working heart-failure regimen on a syndrome that may be the benign one, and start low-dose prednisone rather than an NSAID for symptom control, since naproxen in stage 3b disease with an EF of 28% would put both organs at risk to treat a joint. Monitoring follows ANCA and urine sediment, not the anti-histone titer, which tracks the syndrome that is not the dangerous one. An ANCA-positive result or an active sediment stops the drug outright, whatever it costs his heart failure.
Not agreed: whether continuing a known causative drug even for the days until the serology returns was ever the right default — the rheumatologist's position that the textbook answer should hold regardless of cost wasn't withdrawn, only outweighed by the cardiologist's point that a man with no remaining heart-failure options should not lose the one that works on a presumption the pending tests can settle. Both accepted that the reassurance the case opened on, that this syndrome spares kidneys, had been doing more work than it could bear.